MX2013000491A - Conjugados de anticuerpos multifuncionales. - Google Patents
Conjugados de anticuerpos multifuncionales.Info
- Publication number
- MX2013000491A MX2013000491A MX2013000491A MX2013000491A MX2013000491A MX 2013000491 A MX2013000491 A MX 2013000491A MX 2013000491 A MX2013000491 A MX 2013000491A MX 2013000491 A MX2013000491 A MX 2013000491A MX 2013000491 A MX2013000491 A MX 2013000491A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- seq
- mac
- further characterized
- effector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36350710P | 2010-07-12 | 2010-07-12 | |
| PCT/IB2011/053092 WO2012007896A1 (en) | 2010-07-12 | 2011-07-11 | Multifunctional antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013000491A true MX2013000491A (es) | 2013-02-26 |
Family
ID=44630490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013000491A MX2013000491A (es) | 2010-07-12 | 2011-07-11 | Conjugados de anticuerpos multifuncionales. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8741291B2 (enExample) |
| EP (1) | EP2593142B8 (enExample) |
| JP (2) | JP5913307B2 (enExample) |
| KR (1) | KR20130050966A (enExample) |
| CN (1) | CN103096933A (enExample) |
| AR (1) | AR082205A1 (enExample) |
| AU (1) | AU2011277999A1 (enExample) |
| BR (1) | BR112013000951A2 (enExample) |
| CA (1) | CA2804185C (enExample) |
| CO (1) | CO6670522A2 (enExample) |
| ES (1) | ES2704223T3 (enExample) |
| MX (1) | MX2013000491A (enExample) |
| PE (1) | PE20130643A1 (enExample) |
| PH (1) | PH12013500070A1 (enExample) |
| RU (1) | RU2012157167A (enExample) |
| SG (1) | SG186451A1 (enExample) |
| TW (1) | TWI432213B (enExample) |
| WO (1) | WO2012007896A1 (enExample) |
| ZA (1) | ZA201300161B (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012059873A2 (en) | 2010-11-05 | 2012-05-10 | Covx Technologies Ireland, Ltd. | Anti-diabetic compounds |
| MX350954B (es) * | 2011-06-21 | 2017-09-26 | Immunogen Inc | Derivados de maitansinoides novedosos con enlazador de peptido y conjugados de estos. |
| TWI589592B (zh) | 2011-11-17 | 2017-07-01 | 輝瑞股份有限公司 | 胞毒性肽類以及其抗體藥物共軛體 |
| JP6413127B2 (ja) * | 2012-01-09 | 2018-10-31 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 変異抗体およびそのコンジュゲーション |
| WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体－薬物コンジュゲート |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CA2890571A1 (en) | 2012-11-07 | 2014-05-15 | Kenneth G. Geles | Anti-notch3 antibodies and antibody-drug conjugates |
| HK1214161A1 (zh) | 2012-11-07 | 2016-07-22 | 辉瑞公司 | 抗IL-13受体α2抗体和抗体-药物缀合物 |
| EP2917238A1 (en) | 2012-11-08 | 2015-09-16 | Eleven Biotherapeutics, Inc. | Il-6 antagonists and uses thereof |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| CN105829543B (zh) * | 2013-10-14 | 2021-06-01 | 西纳福克斯股份有限公司 | 糖基改造的抗体、抗体-缀合物及其制备方法 |
| CN105814213B (zh) * | 2013-10-14 | 2021-05-04 | 西纳福克斯股份有限公司 | 经修饰的糖蛋白、蛋白质-缀合物及其制备方法 |
| PT3088419T (pt) | 2013-12-25 | 2019-01-11 | Daiichi Sankyo Co Ltd | Conjugado de anticorpo anti-trop2-fármaco |
| HRP20190431T1 (hr) | 2014-01-31 | 2019-04-19 | Daiichi Sankyo Company, Limited | Anti-her2 antitijelo-lijek konjugat |
| FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
| ES2754348T3 (es) | 2014-04-10 | 2020-04-17 | Daiichi Sankyo Co Ltd | Conjugado de (anticuerpo anti-HER2)-fármaco |
| CN111228511B (zh) | 2014-04-10 | 2024-06-18 | 第一三共株式会社 | 抗her3抗体-药物偶联物 |
| US11142571B2 (en) | 2014-11-07 | 2021-10-12 | Sesen Bio, Inc. | IL-6 antibodies |
| TWI614264B (zh) * | 2015-05-20 | 2018-02-11 | 免疫功坊股份有限公司 | 含胜肽核的多臂接合物及其應用 |
| MX389687B (es) * | 2015-06-19 | 2025-03-20 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas en cys80. |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US9623118B2 (en) * | 2015-09-01 | 2017-04-18 | Immunwork Inc. | Multi-arm linker constructs for treating pathological blood clots |
| EP3349795B1 (en) * | 2015-09-17 | 2021-03-17 | The Scripps Research Institute | Dual variable domain immunoconjugates and uses thereof |
| WO2017070654A1 (en) * | 2015-10-23 | 2017-04-27 | Sorrento Therapeutics, Inc. | Programmable universal cell receptors and methods of using the same |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| US20220008553A1 (en) * | 2015-11-23 | 2022-01-13 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof |
| CN107029244B (zh) * | 2016-02-04 | 2021-04-27 | 浙江昭华生物医药有限公司 | 抗her2抗体-药物偶联物及其应用 |
| JP2019518017A (ja) | 2016-02-09 | 2019-06-27 | アレクサンダー・クランツ | トレースレス親和性標識を使用したタンパク質の部位選択的官能化 |
| EP3419599A4 (en) | 2016-02-23 | 2019-09-11 | Sesen Bio, Inc. | IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| WO2018138591A1 (en) | 2017-01-24 | 2018-08-02 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
| TWI855528B (zh) | 2017-05-15 | 2024-09-11 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| JP7248578B2 (ja) | 2017-08-31 | 2023-03-29 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| KR20250084239A (ko) | 2017-08-31 | 2025-06-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| JP2021502418A (ja) * | 2017-11-04 | 2021-01-28 | アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド | ポリペプチドを修飾するための組成物及び方法 |
| WO2019140216A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| HRP20240756T1 (hr) | 2018-05-18 | 2024-09-13 | Daiichi Sankyo Co., Ltd. | Anti-muc1-eksatekan antitijelo-lijek konjugat |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| EP3831412A4 (en) | 2018-07-31 | 2022-04-27 | Daiichi Sankyo Company, Limited | TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| JP7448638B2 (ja) * | 2019-08-19 | 2024-03-12 | 沈陽薬科大学 | 抗体の変異体及びその使用 |
| EP4025255A1 (en) | 2019-09-04 | 2022-07-13 | Bolt Biotherapeutics, Inc. | Immunoconjugate synthesis method |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス， インコーポレイテッド | Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート |
| CN118201640A (zh) * | 2021-11-01 | 2024-06-14 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物 |
| EP4508091A1 (en) * | 2022-04-15 | 2025-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| CN117801107A (zh) | 2022-09-30 | 2024-04-02 | 上海迪诺医药科技有限公司 | 苯并氮杂卓衍生物、含其的偶联物及其应用 |
| EP4674840A1 (en) | 2023-02-28 | 2026-01-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Chemical coupling linker and use thereof |
| CN118805740B (zh) * | 2024-08-07 | 2025-12-19 | 中国中医科学院中药研究所 | 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| CA2389250C (en) | 1999-10-08 | 2010-07-20 | The Scripps Research Institute | Antibody catalysis of enantio- and diastereo-selective aldol reactions |
| PA8535501A1 (es) | 2001-01-05 | 2003-07-28 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| US7217845B2 (en) * | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
| DK1656391T3 (da) | 2003-08-13 | 2011-01-03 | Pfizer Prod Inc | Modificerede humane IGF-1R antistoffer |
| EP1853294A4 (en) | 2005-03-03 | 2010-01-27 | Covx Technologies Ireland Ltd | ANTIANGIOGENIC COMPOUNDS |
| JP4897050B2 (ja) * | 2006-11-10 | 2012-03-14 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗血管形成化合物 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| AU2008295506A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Anti-IGF-1R antibodies and uses thereof |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| US8293714B2 (en) | 2008-05-05 | 2012-10-23 | Covx Technology Ireland, Ltd. | Anti-angiogenic compounds |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
-
2011
- 2011-07-11 JP JP2013519199A patent/JP5913307B2/ja active Active
- 2011-07-11 KR KR1020137003413A patent/KR20130050966A/ko not_active Ceased
- 2011-07-11 BR BR112013000951A patent/BR112013000951A2/pt not_active Application Discontinuation
- 2011-07-11 WO PCT/IB2011/053092 patent/WO2012007896A1/en not_active Ceased
- 2011-07-11 CN CN2011800438472A patent/CN103096933A/zh active Pending
- 2011-07-11 EP EP11745833.1A patent/EP2593142B8/en active Active
- 2011-07-11 AR ARP110102486A patent/AR082205A1/es not_active Application Discontinuation
- 2011-07-11 PE PE2013000052A patent/PE20130643A1/es not_active Application Discontinuation
- 2011-07-11 AU AU2011277999A patent/AU2011277999A1/en not_active Abandoned
- 2011-07-11 RU RU2012157167/10A patent/RU2012157167A/ru not_active Application Discontinuation
- 2011-07-11 MX MX2013000491A patent/MX2013000491A/es unknown
- 2011-07-11 PH PH1/2013/500070A patent/PH12013500070A1/en unknown
- 2011-07-11 SG SG2012094983A patent/SG186451A1/en unknown
- 2011-07-11 ES ES11745833T patent/ES2704223T3/es active Active
- 2011-07-11 CA CA2804185A patent/CA2804185C/en active Active
- 2011-07-12 TW TW100124612A patent/TWI432213B/zh not_active IP Right Cessation
- 2011-11-28 US US13/305,354 patent/US8741291B2/en active Active
-
2013
- 2013-01-07 ZA ZA2013/00161A patent/ZA201300161B/en unknown
- 2013-01-11 CO CO13004943A patent/CO6670522A2/es unknown
-
2015
- 2015-12-21 JP JP2015248537A patent/JP6339995B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2804185C (en) | 2017-03-21 |
| JP6339995B2 (ja) | 2018-06-06 |
| WO2012007896A1 (en) | 2012-01-19 |
| KR20130050966A (ko) | 2013-05-16 |
| CO6670522A2 (es) | 2013-05-15 |
| EP2593142B8 (en) | 2018-12-26 |
| TWI432213B (zh) | 2014-04-01 |
| US8741291B2 (en) | 2014-06-03 |
| JP2013534535A (ja) | 2013-09-05 |
| AR082205A1 (es) | 2012-11-21 |
| PE20130643A1 (es) | 2013-06-07 |
| CN103096933A (zh) | 2013-05-08 |
| SG186451A1 (en) | 2013-01-30 |
| ZA201300161B (en) | 2013-09-25 |
| CA2804185A1 (en) | 2012-01-19 |
| JP2016094455A (ja) | 2016-05-26 |
| AU2011277999A1 (en) | 2013-01-10 |
| ES2704223T3 (es) | 2019-03-15 |
| EP2593142B1 (en) | 2018-10-10 |
| JP5913307B2 (ja) | 2016-04-27 |
| TW201216986A (en) | 2012-05-01 |
| US20120201809A1 (en) | 2012-08-09 |
| BR112013000951A2 (pt) | 2016-05-17 |
| PH12013500070A1 (en) | 2017-08-23 |
| RU2012157167A (ru) | 2014-08-20 |
| EP2593142A1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI432213B (zh) | 多功能抗體共軛物類 | |
| AU2016363373A1 (en) | Site specific HER2 antibody drug conjugates | |
| US20250277030A1 (en) | Anti-napi2b antibodies and methods of use | |
| TW202421137A (zh) | 靶向ＮａＰｉ２ｂ之抗體—藥物結合物及使用方法 | |
| JP2019505520A (ja) | 抗体およびその薬物コンジュゲートの製剤 | |
| WO2023178451A1 (en) | Anti-folate receptor alpha antibodies and methods of use | |
| EP4696329A1 (en) | Anti-ror1 antibody and drug conjugate thereof | |
| CN118791622A (zh) | 抗ror1抗体及其药物偶联物 | |
| EP4519309A1 (en) | Antibody variable domains and antibodies having decreased immunogenicity | |
| CN111840571B (zh) | 一种抗体药物偶联物及其用途 | |
| HK1188384A (en) | Multifunctional antibody conjugates | |
| WO2025184730A1 (en) | Antibody constructs binding folate receptor alpha and napi2b, conjugates and methods of use | |
| WO2025237392A1 (zh) | 新型抗egfr抗体、药物偶联物及其用途 | |
| TW202530268A (zh) | 抗ｎａｐｉ２ｂ抗體－藥物結合物及使用方法 | |
| WO2024065056A1 (en) | Antibody drug conjugates targeting c-met and methods of use | |
| EA052759B1 (ru) | Антитела против pd-l1 и конъюгаты антитело-лекарственное средство |